• Test Code:
  • Department:
    Molecular Genetics
  • Test Synonyms:
    Achromatopsia Sequencing • Autosomal Recessive Stargardt Disease Pingelapese Achromatopsia • Pingelapese Blindness; Rod Monochromatism 2
  • CPT Code(s):
    Contact KDL for billing information
Background:

Achromatopsia is characterized by reduced visual acuity (<0.1 or 20/200), nystagmus, sensitivity to light, small central scotoma, eccentric fixation and reduced or complete loss of color discrimination.  The diagnosis is based on color vision testing, electroretinography, and fundus examination.  Known genetic causes of this disorder are mutations in the cone cell subunits alpha, CNGA3, and beta, CNGB3.  Mutations in CNGB3 account for 50% of the affected individuals1,2, and 25% harbor mutations in CNGA33,4.

Reasons for Referral:

  • Confirmation of clinical diagnosis in patients with classical or atypical Achromatopsia.
  • Carrier testing of family members of Achromatopsia patients with known mutations.

For detailed information and ordering instructions, please refer to Full Gene Analysis (1240). Genes may be added or removed from the list below if clinically indicated.

The 2 Achromatopsia-associated genes are listed below:
CNGA3, CNGB3

Methodology:

Specimen Requirements:

Test Performed (Days):

Turn Around Time:

Shipment Sensitivity Requirements:

References:

  1. Kohl, et al. Eur J Hum Genet 13, 302-308 (2005).
  2. Kohl, et al. Hum Mol Genet 9, 2107-2116 (2000).
  3. Wissinger, et al. Am J Hum Genet 69, 722-737 (2001).
  4. Kohl, et al. Nat Genet 19, 257-259 (1998).
  5. Human Genome Mutation Database: http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CNGA3.

Additional Info:



Contact Us
Innovations in Testing
View All Tests

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More